In addition, as the predictive accuracy of the combined evaluation of primary tumor sidedness and “PRESSING panel” assessment in predicting the anti-EGFR treatment outcome is around 80%, the “positive” identification of patients with mCRC characterized by a real EGFR pathway-addiction is now extremely appealing. This evidence concerns the gene EGFR and neoplasm.